Work

COLUMBUS part 1–7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma

Year: 2025

Type: article

Abstract: This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.

Source: Future Oncology

DOI: 10.1080/14796694.2025.2536459

Author: Dirk Schadendorf

Institutions: Essen University Hospital, University of Duisburg-Essen

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Pfizer, Array BioPharma